ClinicalTrials.gg
TerminatedNCT04648020VOICEUpdated May 31, 2023

Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.

A Phase 2/3 interventional study of Clonidine HCl Mucoadhesive Buccal Tablet and Placebo Mucoadhesive Buccal Tablet in Chemoradiotherapy-Induced Severe Oral Mucositis, sponsored by Monopar Therapeutics. Terminated at 74 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-31.

Sponsored by Monopar Therapeutics · Phase 2/3, Interventional, and Supportive care

How we know

Why this study was terminated
Interim Analysis did not meet the pre-defined threshold for efficacy of a 15% absolute difference in SOM prevention between Validive and placebo.

From the registry’s dates

  • Primary completion was May 2023, 3 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 75 studies in Mucositis with a site in United States — 3 open to participants now, 4 under way, none of them phase 3. Mucositis · United States.

Enrollment
5th of 68
190 · median 33
Started
2021
with 2 others
Phase 2/3
Only one
of the 75
Registered
65th of 75
by date

Among the 75 studies in Mucositis with a site in United States, this one is the 5th largest by enrollment of the 68 interventional ones that give a count, is one of 3 that started in 2021, is the only one in phase 2/3, and was the 65th registered.

Mucositis

265 studies on the registry are indexed under Mucositis; 34 are open to participants now.

Browse Mucositis studies →

Open to participants now

3 of the 75 studies in Mucositis with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Mucositis studies recruiting now, 13 (62%) set no upper age limit and 7 (33%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 75 studies in Mucositis with a site in United States, or all of them as a file.
02

Study summary

This study is being performed to evaluate the effectiveness of a new drug, clonidine HCl MBT, to prevent the onset of severe oral mucositis (SOM) in patients with oropharyngeal cancer (OPC) who are being treated with chemoradiotherapy. OPC occurs on the back of the tongue or throat and is often treated by the use of chemoradiotherapy, where radiation is localized to these areas. Radiation to the OPC affected tissues causes the release of small proteins called cytokines that cause damage to the area surrounding the tumor including the oral cavity. This damage is characterized by the formation of mucositis which includes redness, pain and ulcers in the mouth and back of the throat. In addition, as more chemoradiation is administered to treat OPC, the inability to eat a solid diet (a Grade 3 mucositis) or to consume anything at all by mouth (a Grade 4 mucositis) occurs in many patients. Collectively, Grade 3 and Grade 4 mucositis is referred to as SOM. It is a frequent, debilitating side effect of chemoradiation in OPC that may cause patients to stop or interrupt their treatment, develop other side effects like the inability to swallow, or require the increased use of pain medications. OPC survivors who have successful treatment of their tumors often develop permanent swallowing, speaking and range of motion issues that may be linked back to the inability to eat and/or drink caused by SOM during their chemoradiotherapy treatment. Clonidine may inhibit the production of cytokines that cause SOM and clonidine HCl mucoadhesive buccal tablet (MBT) has been designed to deliver sustained high levels of clonidine in the oral cavity, potentially decreasing cytokine production and leading to a decrease in the incidence of SOM. Clonidine HCl MBT is a once per day treatment provided as a tablet that a patient may self-administer to the gums, where it sticks tightly to release clonidine over many hours. The primary objective of this Phase 2b/3 study is to evaluate whether clonidine HCl MBT is more effective than placebo MBT in decreasing the incidence of SOM.

Read the detailed description

This is a sequential design Phase 2b/3 multicenter, randomized (1:1), double-blind, placebo-controlled, parallel group study to compare the efficacy and safety of clonidine HCl MBT to placebo MBT in the prevention of severe oral mucositis (SOM) in patients with oropharyngeal cancer (OPC) undergoing chemoradiotherapy (CRT). Best supportive care (BSC) will be allowed as per individual institutional practice with some exceptions as described in the inclusion and exclusion criteria. Eligible patients will be randomized to receive either clonidine MBT or placebo. Patients will be centrally randomized in a 1:1 ratio. The randomization will be stratified by p16 status (positive or negative). Randomized patients will be required to self-apply the study drug to the gum once a day in addition to BSC. The first application of MBT study drug will be performed on Day 1 of the CRT regimen. Each site will require the patient to follow the same local practice for BSC per Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO) guidelines with some exceptions as described in the inclusion and exclusion criteria. Daily, self-administered MBT study drug will be continued once daily for the entire duration of CRT treatment; defined as from Day 1 of CRT until the last day of CRT (anticipated to be approximately 4-8 weeks depending on the patient's prescribed CRT plan). Patients will be recruited sequentially into either the Phase 2b or the Phase 3 part of the study. An interim analysis will be conducted when Phase 2b patients have either completed their CRT or discontinued from the study. The Data Monitoring Committee (DMC) will review the Phase 2b efficacy and safety data at the interim analysis and will make a recommendation on proceeding with the Phase 3 part of the study.

03

Conditions studied

  • Chemoradiotherapy-Induced Severe Oral Mucositis

Keywords

  • Mucositis
  • Oropharyngeal Cancer
  • Clonidine
  • Chemoradiotherapy
  • Severe Oral Mucositis
  • Monopar
  • Oral Mucositis
  • Head and Neck Cancer
  • Oral Cavity
  • Oropharynx
  • Mouth Sores
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male/Female patients of ≥ 18 years of age. Patients with or pathologically confirmed squamous cell carcinoma of the oropharynx (including tonsils or the base of tongue) at one or several sites.
  2. Patients treated with surgical resection of their primary tumor for localized or locally advanced disease T ≥ T0 and/or N ≥ N1 without distant (M0) (American Joint Committee on Cancer - AJCC 8th edition) and initiating adjuvant concurrent CRT within 8 weeks post-operatively. Unknown primary with node-positive disease confirmed to be Squamous Cell Carcinoma would be allowed or Patients who will be treated with definitive concurrent CRT for locally advanced disease T ≥ T0 and/or N ≥ N1 M0 (American Joint Committee on Cancer - AJCC 8th edition).
  3. Patients eligible to receive a continuous course of external fractionated irradiation [conventional or intensity modulated radiation therapy (IMRT)] based on a daily dosing of 1.8 to 2.2 Gy/day 5 days/week in combination with cisplatin monotherapy either every 3 weeks (100 mg/m2) or weekly cisplatin (40 mg/m2). Alternative treatment regimens are allowed only if cisplatin is . The decision on which cisplatin regimen to use in combination with IMRT and study drug/placebo will be at the discretion of the investigator.
  4. Radiation plan must include delivery of a cumulative dose of 60-72 Gy. The oropharynx should receive at least 50 Gy.
  5. Patients with adequate laboratory values defined as:

    1. ≥ 1.5 × 10\^9/L
    2. count ≥ 75 × 10\^9/L
    3. ≥ 9 g/dL
    4. Creatinine blood level ≤ 1.5 × (ULN)
    5. Total ≤ 1.5 × ULN; patients with Gilbert's Syndrome can be included if hyperbilirubinemia ≤ 3 × ULN
    6. Serum (AST) and alanine aminotransferase (ALT) ≤ 3 × ULN
  6. Patients with (ECOG) performance status of 0 or 1. A performance status of 2 is allowed only if due to a patient's .
  7. Patients must provide written .
  8. Human Papillomavirus (HPV) status documented by immunohistochemical detection of p16 expression in the tumor.
  9. Negative serum pregnancy test for females of at screening. A female is eligible to enter and participate in the study if the female is of non-child-bearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had a hysterectomy, a bilateral oophorectomy (ovariectomy), a bilateral tubal ligation, or is with a minimum of 1 year without menses.
  10. Males with female partners of child-bearing potential and females of child-bearing potential must agree to use effective starting prior to the first day of study drug treatment and continuing for 3 months after the last dose of study drug MBT.
  11. Patients must be willing to complete questionnaires on a tablet, home computer, or paper form.

Exclusion criteria

Exclusion Criteria:

  1. Patients with no tumor or lesion in the oropharynx.
  2. Prior induction chemotherapy for treatment of current .
  3. Patients with planned accelerated IMRT.
  4. Evidence of a concomitant other malignancy and/or any prior malignancy without complete remission in the last 2 years, except adequately treated basal or squamous cell carcinoma of the skin or in situ cervical cancer.
  5. Patients with OM at baseline, any other oral ulceration or active oral infection (e.g., aphthous ulcers, orofacial herpes). Patients with post-operative pain of the mouth or throat are eligible.
  6. Patients with known (HIV) seropositivity, known active or C or known active tuberculosis.
  7. Patients with systolic blood pressure (BP) \< 100 mmHg and/or diastolic BP \< 50 mmHg.
  8. Patients with symptomatic cardiac dysrhythmia.
  9. Patients with recent (less than 6 months) acute cardiovascular diseases (i.e., stroke, myocardial infarction).
  10. Patients with any clinical condition, psychiatric condition, or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with study requirements and follow-up visits.
  11. Patients currently being treated with sultopride, clonidine hydrochloride (eg, Catapres®), pentoxifylline or pilocarpine.
  12. Patients intended to be treated specifically to prevent OM with any of the following:

    a. Bioadherent agents and mouthwashes: i. GelClair (consists of polyvinylpyrrolidone, hyaluronic acid, and glycyrrhetinic acid) ii. Sucralfate iii. Episil mouth spray iv. MuGard oral mucoadhesive v. Saforis (L-glutamine (topical)) b. Drug therapies and biologics: i. Amifostine (and similar free radical scavenger/antioxidant medications) ii. Palifermin (recombinant human keratinocyte growth factor-(KGF-1)) iii. Glutamine b. Interventional therapies i. Low level laser therapy (LLLT)

  13. Patients who are unable to tolerate oral diet and/or are feeding tube dependent at baseline.
  14. Patients receiving an approved or an anti-cancer agent other than those specified in this study.
  15. Patients with a known to clonidine or any of the MBT .
  16. Women who are pregnant or breast-feeding.
  17. Patients whose medical, psychological or surgical conditions are unstable and may affect the study completion and/or compliance and/or the ability to give .
  18. Men and women of child-bearing age and their respective partners unwilling to use a highly effective method during the study and for 3 months after the last administration of study drug.
  19. Patient who has participated in another clinical trial with an investigational drug in the last 30 days prior to randomization in the present clinical study.
  20. Subjects with orthostatic hypotension, defined by a decrease of systolic BP and/or diastolic BP above 20 mmHg when the patient stands up.
  21. Conditions including but not limited to COVID-19 which would confound the assessment of the effects and/or safety of study medication in the opinion of the investigator.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
190 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo Mucoadhesive Buccal Tablet given daily during chemoradiotherapy

    Drug: Placebo Mucoadhesive Buccal Tablet

  • Experimental
    Clonidine HCl Mucoadhesive Buccal Tablet (MBT)

    Clonidine HCl MBT given daily during chemoradiotherapy

    Drug: Clonidine HCl Mucoadhesive Buccal Tablet

Interventions

  • DrugClonidine HCl Mucoadhesive Buccal Tablet

    100 μg of clonidine per tablet

    Also known as: Validive®

  • DrugPlacebo Mucoadhesive Buccal Tablet

    Placebo

06

What researchers measure

Primary outcomes

  1. To demonstrate the efficacy of HCl MBT to prevent SOM in OPC patients receiving CRT.

    The occurrence of SOM (Yes/No), defined as any reporting of World Health Organization (WHO) Grade 3-4 OM, from the first day to the last day of CRT. The WHO mucositis grading scale will be used to assess the occurrence of SOM in this trial. The WHO grading scale grades OM from 0 to 4 according to severity of clinical observation and functional limitation, with Grade 4 = oral alimentation impossible, Grade 3 = Oral ulcers, liquid diet only, Grade 2 = Oral erythema, ulcers, solid diet tolerated, Grade 1 = Oral soreness, erythema, and Grade 0 = normal, no mucositis (no signs, no symptoms).

    Time frame: From the first CRT treatment through the end of the study treatment period, which is estimated to be 7 weeks.

Secondary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]

    Evaluate the safety and tolerability of administering HCl MBT to OPC patients receiving CRT by assessing the number and severity of treatment-emergent adverse events (TEAE) and specifically those TEAEs of special interest. Adverse events are graded and tabulated using NCI CTCAE v5.0.

    Time frame: Up to 1 year after the first dose

07

Study locations

74 sites
  • University of Arkansas for Medical Sciences
    Little Rock, Arkansas 72205, United States
  • Orange Coast Memorial Medical Center
    Fountain Valley, California 92708, United States
  • Long Beach Memorial Medical Center
    Long Beach, California 90806, United States
  • Pomona Valley Hospital Medical Center
    Pomona, California 91767, United States
  • Grand Valley Oncology
    Grand Junction, Colorado 81505, United States
  • Christiana Care Health Services
    Newark, Delaware 19713, United States
  • Boca Raton Regional Hospital
    Boca Raton, Florida 33486, United States
  • Miami Cancer Institute
    Miami, Florida 33176, United States
  • Memorial Healthcare System
    Pembroke Pines, Florida 33028, United States
  • University Cancer & Blood Center
    Athens, Georgia 30607, United States
  • IACT Health (Centricity Research)
    Columbus, Georgia 31904, United States
  • Decatur Memorial Hospital
    Decatur, Illinois 62526, United States
  • Edward Elmhurst Health
    Elmhurst, Illinois 60126, United States
  • NorthShore University Health Systems
    Evanston, Illinois 60201, United States
  • AMITA Health
    Hinsdale, Illinois 60521, United States
  • UnityPoint Health
    Cedar Rapids, Iowa 52403, United States
  • Des Moines Oncology Research Association
    Des Moines, Iowa 50309, United States
  • East Jefferson General Hospital
    Metairie, Louisiana 70006, United States
  • Louisiana State University Health - Shreveport
    Shreveport, Louisiana 71103, United States
  • Willis-Knighton Cancer Center
    Shreveport, Louisiana 71103, United States
  • Greater Baltimore Medical Center
    Baltimore, Maryland 21204, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Cox Medical Centers
    Springfield, Missouri 65807, United States
  • Summit Health
    Florham Park, New Jersey 07932, United States
  • New York Cancer and Blood Specialists
    New York, New York 10028, United States
  • Northwell Health
    New York, New York 11042, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27514, United States
  • Novant Health Cancer Institute
    Charlotte, North Carolina 28204, United States
  • CaroMont Regional Medical Center
    Gastonia, North Carolina 28054, United States
  • Novant Health Cancer Institute - Forsyth
    Winston-Salem, North Carolina 27103, United States
  • Summa Health System
    Akron, Ohio 44304, United States
  • University of Cincinnati Medical Center
    Cincinnati, Ohio 45219, United States
  • Mercy Health
    Youngstown, Ohio 44501, United States
  • Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Oklahoma Cancer Specialists
    Tulsa, Oklahoma 74146, United States
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
  • AHN Cancer Institute - Allegheny General
    Pittsburgh, Pennsylvania 15212, United States
  • Mary Hillman Radiation Oncology Center at UPMC Shadyside
    Pittsburgh, Pennsylvania 15232, United States
  • Reading Hospital
    West Reading, Pennsylvania 19611, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Charleston Oncology
    Charleston, South Carolina 29406, United States
  • Ballad Health
    Johnson City, Tennessee 37604, United States
  • Hendrick Cancer Center
    Abilene, Texas 79601, United States
  • Eastern Virginia Medical School
    Norfolk, Virginia 23507, United States
  • PeaceHealth
    Bellingham, Washington 98225, United States
  • Providence Regional Cancer Partnership
    Everett, Washington 98201, United States
  • Benaroya Research Institute at Virginia Mason
    Seattle, Washington 98101, United States
  • HSHS St. Vincent Hospital Cancer Centers at HSHS St. Vincent Hospital
    Green Bay, Wisconsin 54301, United States
  • Institut Andree Dutreix / Centre de Cancerologie Dunkerque
    Coudekerque-Branche, Dunkerque 59210, France
  • Centre Hospitalier Universitaire Amiens-Picardie
    Amiens, 80054, France
  • Centre Hospitalier Universitaire Morvan / Centre Hospitalier Universitaire de Brest
    Brest, 29609, France
  • Centre hopitalier intercommunal de Créteil
    Créteil, 94000, France
  • Centre Hospitalier de Dax-Côte d'Argent
    Dax, 40100, France
  • Clinique François Chénieux
    Limoges, 87039, France
  • Hôpital Saint Joseph
    Marseille, 13008, France
  • Centre Hospitalier Universitaire La miletrie
    Nice, 06000, France
  • Institut Jean Godinot
    Reims, 51100, France
  • CHU de Saint Etienne
    Saint-Priest-en-Jarez, 42270, France
  • Institut Gustave Roussy, Desmoulins
    Villejuif, 94800, France
  • Universitatsklinikum Freiburg
    Freiburg, 79106, Germany
  • Klinikum Kassel GmbH
    Kassel, 34125, Germany
  • Caritas Klinikum Saarbrucken St. Theresia
    Saarbrücken, 66113, Germany
  • Ponce Medical School Foundation
    Ponce, 00717, Puerto Rico
  • Hospital Universitari Son Espases
    Palma, Balearic Islands 07120, Spain
  • Hospital Universitario Cruces de Bilbao
    Barakaldo, Bizkaia 48903, Spain
  • Hospital Meixoeiro
    Vigo, Pontevedra 36214, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Institut Català d'Oncologia Hospitalet (Hospital Duran i Reynals)
    Barcelona, 08908, Spain
  • Hospital Universitario Quirónsalud Madrid
    Madrid, 28223, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, 28222, Spain
  • Hospital Universitari Son Llàtzer
    Palma De Mallorca, 07098, Spain
  • Hospital Complejo Universitario de Navarra
    Pamplona, 31008, Spain
  • Hospital de Donostia
    San Sebastián, 20014, Spain
  • Hospital Clínico Universitario Santiago de Compostela
    Santiago de Compostela, 15706, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in May 2023, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2020
First posted
Dec 1, 2020
StartActual
Feb 11, 2021
Primary completionActual
May 14, 2023
CompletionActual
May 14, 2023
Last update
May 31, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04648020
Lead sponsor
Monopar Therapeutics
Responsible party
Sponsor
First posted
Dec 1, 2020
Start date
Feb 11, 2021
Primary completion
May 14, 2023
Completion
May 14, 2023
Last update
May 31, 2023

Study contacts

Holli Carlson
study director · Monopar Therapeutics Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion